- Home
- CE vs MIRM Comparison
CE vs MIRM Comparison
Compare CE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CE | MIRM |
|---|---|---|
| Founded | 1918 | 2018 |
| Country | United States | United States |
| Employees | 11434 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CE | MIRM |
|---|---|---|
| Price | $48.24 | $110.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $64.29 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.4M | 708.9K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | 23.62 | ★ 74.59 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $9,544,000,000.00 | $19,138,000.00 |
| Revenue This Year | $3.14 | $26.22 |
| Revenue Next Year | $2.83 | $22.04 |
| P/E Ratio | $124.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.13 | $47.89 |
| 52 Week High | $70.70 | $114.99 |
Technical Indicators
Market Signals| Indicator | CE | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 68.38 |
| Support Level | $47.67 | $87.93 |
| Resistance Level | $48.41 | $114.99 |
| Average True Range (ATR) | 2.22 | 3.85 |
| MACD | -0.02 | 1.58 |
| Stochastic Oscillator | 0.67 | 98.05 |
Price Performance
Historical ComparisonAbout CE Celanese Corporation
Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.